COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

  • STATUS
    Recruiting
  • End date
    Mar 16, 2022
  • participants needed
    200
  • sponsor
    Novartis Pharmaceuticals
Updated on 14 July 2021
Investigator
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (5.6 mi away) Contact
+32 other location
ejection fraction
heart failure
chronic heart failure
sham treatment
enalapril
valsartan
lcz696
angiotensin ii receptor antagonists

Summary

The purpose of this study is to determine the effect of LCZ696 vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and erectile dysfunction

Details
Condition Heart failure, Heart disease, Impotence, systolic heart failure, Congestive Heart Failure, Erectile Dysfunction, Cardiac Disease, cardiac failure, congestive heart disease
Treatment Enalapril, enalapril matching placebo, LCZ696, LCZ696 matching placebo
Clinical Study IdentifierNCT03917459
SponsorNovartis Pharmaceuticals
Last Modified on14 July 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note